Medicenna Announces Results of Annual Meeting of Shareholders

GlobeNewswireSep 26 17:00 ET

Medicenna Presents Preclinical Results From Its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference

GlobeNewswireSep 9 07:32 ET

Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswireSep 5 07:00 ET

Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference

GlobeNewswireAug 27 07:00 ET

Medicenna Reports First "Complete Responder" With MDNA11 Monotherapy, Q1 Results

MT NewswiresAug 1 09:23 ET

Medicenna Brief: Increased Cash Balance to US$37 Million Following a $20 Million Investment by RA Capital Extending Runway Into Mid-2026

MT NewswiresJun 27 08:24 ET